Vera Therapeutics, Inc. Operating Expenses
Vera Therapeutics, Inc. (VERA) reported Operating Expenses of $112.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-10
- Vera Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $112.49M, a 40.37% increase year-over-year.
- Vera Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $125.13M, a 118.79% increase year-over-year.
- Vera Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $94.21M, a 92.60% increase year-over-year.
- Vera Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $83.93M, a 68.53% increase year-over-year.
- Vera Therapeutics, Inc. operating expenses for fiscal 2025 was $315.47M, a 88.71% increase from fiscal 2024.
- Vera Therapeutics, Inc. operating expenses for fiscal 2024 was $167.17M, a 63.87% increase from fiscal 2023.
- Vera Therapeutics, Inc. operating expenses for fiscal 2023 was $102.01M, a 12.22% increase from fiscal 2022.
- Vera Therapeutics, Inc. operating expenses for fiscal 2022 was $90.90M, a 164.24% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $112.49M 10-Q · filed 2026-08-10 | $237.62M 10-Q · filed 2026-08-10 | $331.83M derived: sum of 3 quarters · filed 2026-08-10 | $415.76M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $125.13M 10-Q · filed 2026-05-07 | $219.34M derived: sum of 2 quarters · filed 2026-05-07 | $303.27M derived: sum of 3 quarters · filed 2026-05-07 | $383.41M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $94.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $178.14M derived: sum of 2 quarters · filed 2026-02-26 | $258.28M derived: sum of 3 quarters · filed 2026-08-10 | $315.47M 10-K · filed 2026-02-26 |
| 2025-09-30 | $83.93M 10-Q · filed 2025-11-05 | $164.07M derived: sum of 2 quarters · filed 2026-08-10 | $221.27M 10-Q · filed 2025-11-05 | $270.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $80.14M 10-Q · filed 2026-08-10 | $137.34M 10-Q · filed 2026-08-10 | $186.25M derived: sum of 3 quarters · filed 2026-08-10 | $236.05M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $57.19M 10-Q · filed 2026-05-07 | $106.11M derived: sum of 2 quarters · filed 2026-05-07 | $155.91M derived: sum of 3 quarters · filed 2026-05-07 | $193.25M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $48.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $98.72M derived: sum of 2 quarters · filed 2026-02-26 | $136.06M derived: sum of 3 quarters · filed 2026-02-26 | $167.17M 10-K · filed 2026-02-26 |
| 2024-09-30 | $49.80M 10-Q · filed 2025-11-05 | $87.14M derived: sum of 2 quarters · filed 2025-11-05 | $118.26M 10-Q · filed 2025-11-05 | $145.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $37.34M 10-Q · filed 2025-08-05 | $68.45M 10-Q · filed 2025-08-05 | $95.48M derived: sum of 3 quarters · filed 2026-02-26 | $117.24M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $31.11M 10-Q · filed 2025-05-07 | $58.14M derived: sum of 2 quarters · filed 2026-02-26 | $79.90M derived: sum of 3 quarters · filed 2026-02-26 | $101.87M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $27.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $48.78M derived: sum of 2 quarters · filed 2026-02-26 | $70.75M derived: sum of 3 quarters · filed 2026-02-26 | $102.01M 10-K · filed 2026-02-26 |
| 2023-09-30 | $21.76M 10-Q · filed 2024-11-07 | $43.73M derived: sum of 2 quarters · filed 2024-11-07 | $74.98M 10-Q · filed 2024-11-07 | $108.56M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $21.97M 10-Q · filed 2024-08-08 | $53.23M 10-Q · filed 2024-08-08 | $86.81M derived: sum of 3 quarters · filed 2024-08-08 | $112.05M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $31.26M 10-Q · filed 2024-05-10 | $64.84M derived: sum of 2 quarters · filed 2024-05-10 | $90.08M derived: sum of 3 quarters · filed 2024-05-10 | $105.14M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $33.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $58.83M derived: sum of 2 quarters · filed 2024-03-27 | $73.88M derived: sum of 3 quarters · filed 2024-03-27 | $90.90M 10-K · filed 2024-03-27 |
| 2022-09-30 | $25.24M 10-Q · filed 2023-11-09 | $40.30M derived: sum of 2 quarters · filed 2023-11-09 | $57.32M 10-Q · filed 2023-11-09 | $73.91M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $15.06M 10-Q · filed 2023-08-10 | $32.08M 10-Q · filed 2023-08-10 | $48.66M derived: sum of 3 quarters · filed 2023-08-10 | $55.91M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $17.02M 10-Q · filed 2023-05-11 | $33.61M derived: sum of 2 quarters · filed 2023-05-11 | $40.86M derived: sum of 3 quarters · filed 2023-05-11 | $46.71M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $16.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $23.84M derived: sum of 2 quarters · filed 2023-03-28 | $29.69M derived: sum of 3 quarters · filed 2023-03-28 | $34.40M 10-K · filed 2023-03-28 |
| 2021-09-30 | $7.25M 10-Q · filed 2022-11-09 | $13.10M derived: sum of 2 quarters · filed 2022-11-09 | $17.82M 10-Q · filed 2022-11-09 | $60.38M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $5.85M 10-Q · filed 2022-08-10 | $10.56M 10-Q · filed 2022-08-10 | $53.13M derived: sum of 3 quarters · filed 2022-08-10 | $57.16M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $4.72M 10-Q · filed 2022-05-16 | $47.28M derived: sum of 2 quarters · filed 2022-05-16 | $51.31M derived: sum of 3 quarters · filed 2022-05-16 | $54.49M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $42.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $46.60M derived: sum of 2 quarters · filed 2022-03-28 | $49.77M derived: sum of 3 quarters · filed 2022-03-28 | $52.24M 10-K · filed 2022-03-28 |
| 2020-09-30 | $4.04M 10-Q · filed 2021-11-10 | $7.21M derived: sum of 2 quarters · filed 2021-11-10 | $9.68M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.17M 10-Q · filed 2021-08-16 | $5.64M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $2.47M 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |